Project Grant R43AI155197

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, will provide $178,000 to The Children's Hospital Corporation (Boston Children's Hospital) to develop a human bone marrow organoid system to study Runx1-Familial Platelet Disorder with associated Myeloid Malignancy (Runx1-FPD/MM). The 1-year pilot project aims to generate bone marrow organoids from human induced pluripotent stem cell lines derived from Runx1-FPD patients,...

This Project Grant awarded by the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $650,000 to the Sloan-Kettering Institute for Cancer Research, a non-profit research organization in New York, NY, from September 2024 to June 2028. The project aims to evaluate the use of the interferon-gamma neutralizing monoclonal antibody emapalumab as an early upfront "prophase" therapy for pediatric patients with newly diagnosed acquired aplastic anemia. The goal is to...

This Project Grant from the National Heart, Lung and Blood Institute, part of the Department of Health and Human Services, provides $914,900 to Ship Of Theseus LLC under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports preclinical development of a nuclear-targeting biologic to safely increase stem cell expansion in vivo and accelerate recovery from neutropenia following chemotherapy and bone marrow transplant. Specifically, the grant will advance a patented mutant...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,123,357 in funding to the Children's Hospital Medical Center in Cincinnati, Ohio for a research program focused on understanding the bone marrow microenvironment and its role in regulating blood cell production. The key goals of the 7-year research program are to: 1) Dissect the function of specialized microenvironments that serve as niches for different blood...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $568,264 to SAFI Biotherapeutics Inc., a pre-clinical blood cell therapy company, to develop a scalable bioprocess for manufacturing human red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). The goal is to create a renewable source of designer RBCs with unique antigen profiles to help identify complex antibodies in...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $146,876 to the Coriell Institute for Medical Research to develop new methods for expanding functional hematopoietic stem cells (HSCs) from cryopreserved umbilical cord blood (UCB) samples. The project aims to optimize an approach using PPAR-α agonists, which have been shown to significantly expand long-term functional UCB HSCs...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...

This Project Grant award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $882,247 to the University of Pittsburgh to conduct a Phase 2 clinical trial evaluating the efficacy of interferon-gamma (IFN-γ) and donor lymphocyte infusion (DLI) for treating relapsed myeloid malignancies in patients who have undergone allogeneic stem cell transplantation. The trial aims to enroll 45 participants and will compare outcomes to synthetic control cohorts from the Center...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $169,156 to The Washington University in St. Louis to support a 5-year research program focused on optimizing hematopoietic stem cell transplantation (HSCT) to treat non-malignant diseases, particularly sickle cell disease (SCD). The key objectives are to: 1) Evaluate novel stem cell mobilization regimens combining VLA-4 and CXCR4 inhibition to generate...

The National Cancer Institute has awarded a $275,627 Project Grant to Link Biosystems Inc., a self-certified small disadvantaged business and for-profit organization, to develop the ONXPANSION bioreactor workflow. This workflow aims to enable efficient expansion of patient-derived induced pluripotent stem cells into clinically relevant cell doses to support autologous cell therapy applications. The grant supports efforts to de-risk the utility of Link Biosystems' bioreactor technology for...